Wegovy's Medicare Part D Prospects: Four Million Lives And Counting?

 
• By Cathy Kelly

Novo Nordisk is expecting a relatively modest uptake in Medicare Part D for the cardiovascular claim, but plans still will worry about stemming demand in obesity.

Payers worry demand for Wegovy will be much higher now that there is some access to it in Part D. • Source: Shutterstock

More from Market Access

More from Pink Sheet